Vaxcyte, Inc. Common Stock PCVX

$55.39 -5.09% at last close
Market Cap$9.24 billion
P/E Ratio—
Div Yield—
Volume1.91M
52-Week Range $39.87$90.75

Analyst Ratings

Consensus
Buy — 5 Buy · 0 Hold · 0 Sell (5 analysts)
Avg. Price Target
$117.20 (+111.6% upside)

Full PCVX forecast & analyst actions →

Key Stats

Today's Range
$55.27 – $58.48
50-Day Range
$55.09 – $90.75
52-Week Range
$39.87 – $90.75
Volume
1.91 million shs
Average Volume
1.87 million shs
Market Cap
$9.24 billion
P/E Ratio
—
Dividend Yield
—

Short Interest

Short Interest
0.13%
Days to Cover
1.21

About Vaxcyte, Inc. Common Stock

Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.

Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Employees
507
Exchange
XNAS
Listed
2020-06-12

Related Stocks

Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.